Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses
Experimental Dermatology · 2024
DOI: 10.1111/exd.15177 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Experimental Dermatology, 2024. Verfasst von Elena Peeva und 14 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation and Immunology Research Unit, Pfizer, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Vitiligo, Biomarkers. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Efficacy and safety of ritlecitinib (an oral JAK3/TEC family kinase inhibitor) were evaluated in patients with nonsegmental vitiligo (NSV) across Fitzpatrick skin types (FSTs). Patients with FST I‐III (‘light skin’; n = 247) and FST IV‐VI (‘dark skin’; n = 117) received once‐daily ritlecitinib 50 mg (with/without 4‐week loading dose), low‐dose ritlecitinib or placebo for 24 weeks. At baseline, patients with light skin displayed higher CLM‐1 and NCR1 serum levels than patients with dark skin ( p < 0.05). At 24 weeks, ritlecitinib 50 mg improved the extent of depigmentation measured by percent change from baseline in facial‐vitiligo area scoring index (placebo‐adjusted mean difference [90% CI]) in patients with light (−15.2 [−24.7, −5.8]; p = 0.004) and dark (−37.4 [−50.3, −24.4]; p < 0.0001) skin, with continuous re‐pigmentation through week 48. Treatment‐emergent adverse events were similar across FSTs. At weeks 4 and 24, ritlecitinib 50 mg reduced CXCL11 serum levels ( p < 0.001) in patients with light skin, whereas patients with dark skin had increased levels at week 4 ( p = 0.05) and no significant change at week 24. Ritlecitinib 50 mg decreased IL‐9 and IL‐22 expression levels in dark skin compared with light skin (qPCR; p < 0.05). These differences in immune dysregulations may explain why NSV patients with dark skin respond to therapy earlier than patients with light skin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammation and Immunology Research Unit, Pfizer, Cambridge, Massachusetts, USA.
- Inflammation and Immunology Research Unit, Pfizer, Collegeville, Pennsylvania, USA.
- Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
- Istituto Dermopatico dell Immacolata, IDI, IRCCS, Rome, Italy.
- Cutaneous Physiopathology Laboratory, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
- Clinical Statistics, Pfizer, Cambridge, Massachusetts, USA.
ORCID-Profile: Yuji Yamaguchi, Zhan Ye, Abigail Sloan, Khaled Ezzedine, Ester Del Duca, Johnathan Bar, Paola Facheris, Emma Guttman-Yassky
Förderung
- Pfizer
Zitieren
APA
Peeva, E., Yamaguchi, Y., Ye, Z., King, B., Picardo, M., Sloan, A., Ezzedine, K., Del Duca, E., Estrada, Y., Hassan-Zahraee, M., He, W., Hyde, C., Bar, J., Facheris, P., & Guttman-Yassky, E. (2024). Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses. Experimental Dermatology. https://doi.org/10.1111/exd.15177
Vancouver
Peeva E, Yamaguchi Y, Ye Z, King B, Picardo M, Sloan A, et al. Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses. Experimental Dermatology. 2024. doi:10.1111/exd.15177
BibTeX
@article{Peeva2024,
author = {Peeva, Elena and Yamaguchi, Yuji and Ye, Zhan and King, Brett and Picardo, Mauro and Sloan, Abigail and Ezzedine, Khaled and Del Duca, Ester and Estrada, Yeriel and Hassan-Zahraee, Mina and He, Wen and Hyde, Craig and Bar, Johnathan and Facheris, Paola and Guttman-Yassky, Emma},
title = {Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses},
journal = {Experimental Dermatology},
year = {2024},
doi = {10.1111/exd.15177}
}
EUVIMED